~~<i id='BD0063539E'><strike id='BD0063539E'><tt id='BD0063539E'><pre id='BD0063539E'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：hotspot 2025-09-27 14:22:27 Page View：3

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cheap, fast test for Zika and dengue could cost just $1
Next article： Walensky prepares to leave CDC — and Congress — behind

explore

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

6:14PomKlementieffasMantis,Groot(voicedbyVinDiesel),ChrisPrattasPeterQuill/Star-Lord,DaveBautistaasD

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Teladoc has a new CEO, but challenges remain the same

AdobeVirtualcarecompanyTeladochasanewchiefexecutiveofficerfollowingtheabruptdepartureofitslongtimele

WSS

explore

explore

knowledge

explore

Teladoc has a new CEO, but challenges remain the same